DPYSL2 as a Radioligand Therapy Target
DPYSL2, dihydropyrimidinase like 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, DPYSL2 staining is highest in glioma (90% of samples positive), testicular cancer (100% of samples positive) and neuroendocrine tumors (75% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is DPYSL2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in glioma, 90% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
DPYSL2 expression in cancer
Protein expression of DPYSL2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Glioma | 0.77 | High | 90% |
| Testicular Cancer | 0.64 | High | 100% |
| Neuroendocrine Tumors | 0.58 | High | 75% |
| Kidney Cancer | 0.47 | Medium | 83% |
| Lymphoma | 0.46 | Medium | 82% |
| Head and Neck Cancer | 0.42 | Medium | 75% |
| Melanoma | 0.39 | Medium | 67% |
| Lung Cancer | 0.31 | Medium | 67% |
| Skin Cancer | 0.30 | Medium | 55% |
| Pancreatic Cancer | 0.28 | Medium | 75% |
| Gastric Cancer | 0.28 | Medium | 75% |
| Ovarian Cancer | 0.22 | Medium | 50% |
| Thyroid Cancer | 0.22 | Medium | 33% |
| Colorectal Cancer | 0.21 | Medium | 64% |
| Breast Cancer | 0.20 | Medium | 50% |
| Liver Cancer | 0.15 | Low | 27% |
| Cervical Cancer | 0.12 | Low | 36% |
| Bladder Cancer | 0.08 | Low | 25% |
| Endometrial Cancer | 0.08 | Low | 25% |
Not detected by IHC in: prostate cancer.
Is DPYSL2 internalized?
Nuclens has not yet extracted internalization evidence for DPYSL2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
DPYSL2 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for DPYSL2 yet. Search ClinicalTrials.gov for DPYSL2 trials.
DPYSL2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See DPYSL2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
DPYSL2 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related glioma radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · ITGAV · B7-H3 (CD276) · SSTR2 · STEAP2 · FAP
See all radioligand therapy targets in glioma.
See how DPYSL2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.